IVI has just released the latest update to the organization’s Rheumatoid Arthritis (RA) Value Assessment Model. The updated model now incorporates additional treatment options (triple therapy, Janus Kinase (JAK) inhibitors, sarilumab, and biosimilars), updated treatment effect estimates based on additional randomized controlled trial (RCT) evidence, and updated cost estimates. The model is also designed to answer a variety of critical questions for patients, payers and providers if given real world patient data as input. IVI is now in the process of seeking such data partners.
Read the full press release here.